SRA

Non-Hodgkin's lymphomas (NHL) make up the majority of lymphoma diagnoses and represent a very diverse set of malignancies. We sought to identify kinases uniquely upregulated in different NHL subtypes. Using Multiplexed Inhibitor Bead-mass spectrometry (MIB/MS), we found Tyro3 was uniquely upregulated and important for cell survival in primary effusion lymphoma (PEL). We developed an inhibitor against Tyro3 named UNC3810A, which inhibited cell growth in PEL but not in other NHL subtypes. UNC3810A also significantly inhibited tumor progression in a PEL xenograft mouse model compared to the vehicle treated animals. Our data suggests Tyro3 may be a therapeutic target for PEL. Overall design: RNASeq and analysis of 24 NHL cell lines. RNA was harvested from cell lines using the RNeasy Plus Mini Kit according to manufacturer's instructions. mRNA-Seq libraries were generated using the Stranded mRNA-Seq kit and multiplexed with Illumina TruSeq adapters. Samples were run on two 75-cycle single-end sequencing runs with an Illumina NextSeq-500.